-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology ELISpot Platform
Author:
InnoModels
Release time:
2024-09-06
In the vast starry sky of life science research, InnoModels Biotechnology (Beijing) Co., Ltd. lights a bright light for scientists with its leading ELISpot platform technology. As a high-tech enterprise co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Champion and Shanghai Jiao Tong University Institute of Immunology, InnoModels has not only made remarkable achievements in the field of oncology and tumor immunopharmacodynamics CRO services, translational medicine research services, and individualized healthcare, but also demonstrated extraordinary strengths and capabilities in the areas of immunology, biomedical research, and vaccine development with its ELISpot platform technology. The ELISpot platform technology has demonstrated its extraordinary strength and potential in immunology, biomedical research and vaccine development.
ELISpot platform: the perfect combination of high sensitivity and versatility
ELISpot technology is a highly sensitive method for the detection of substances secreted by individual cells. By optimizing this technology, InnoModels' ELISpot platform enables in-depth analysis of cellular responses and functions, especially in the study of immune cells, such as T cells and B cells, showing unique advantages. The platform not only quantitatively analyzes proteins produced by cells, such as cytokines and antibodies, but also accurately evaluates the function and activity of immune cells, which provides strong support for immune monitoring, vaccine development and cancer immunotherapy.
Customized solutions to meet diverse research needs
InnoModels Bio's ELISpot platform provides a variety of customized solutions to meet the needs of different fields and stages of research. The platform supports multiple CTL (cytotoxic T-lymphocyte) stimulation methods, including the use of human or mouse peripheral blood mononuclear cells (PBMCs) or spleen immune cells for in vitro specific antigen presentation. In addition, the platform enables analysis of CTL responses in peripheral blood or spleen cells after immunization in immunologically sound mice. This flexibility and customizability allows researchers to design the most appropriate experimental protocols based on specific research objectives.

High sensitivity and precise analysis for scientific breakthroughs
InnoModels' ELISpot platform is renowned for its excellent sensitivity and precision analysis capabilities. The platform is capable of detecting extremely low levels of CTL responses, ensuring that researchers can accurately measure and analyze CTL activity in different biological samples. This feature is particularly important in cancer vaccine research, as understanding and monitoring CTL responses is critical for assessing vaccine efficacy and optimizing treatment regimens. In addition, the platform provides the ability to quantitatively and qualitatively analyze the level of CTL production, enabling researchers to comprehensively assess the quantity and quality of CTL responses, providing strong support for scientific breakthroughs.
Wide range of application areas to advance life sciences
InnoModels' ELISpot platform has demonstrated extensive application value in various fields of life science research. In immunology research, the platform can be used to study the function and activity of immune cells and reveal the intrinsic mechanism of immune response; in biomedical research, the platform can be used to assess the impact of drugs on the immune system, providing an important basis for the development of new medicines; in vaccine development, the platform can be used to assess vaccine-induced immune response and optimize vaccine formulation and vaccination strategies. In addition, the platform can also be used in various fields such as research on infectious pathogens and autoimmune diseases, contributing to the overall progress of life science research.
Conclusion
InnoModels Biotechnology (Beijing) Co., Ltd. provides strong support for life science research with its leading ELISpot platform technology. With its high sensitivity, versatility and wide applicability, the platform plays an irreplaceable role in immunology, biomedical research and vaccine development. In the future, as the technology continues to advance and innovate, InnoModels' ELISpot platform will continue to provide scientists with more possibilities and promote the in-depth development of life science research.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd